Artoss, Inc. has elected two new members to its Board of Directors: Charles Emley of angelMD and Gilbert Ortega, M.D., M.P.H. of Sonoran Orthopaedic Trauma Surgeons. Both were elected for one year terms at the recent Artoss annual shareholders meeting.
New Board member Charles Emley is senior advisor and managing partner of angelMD’s Catalyst Fund, a direct investment fund. angelMD and Catalyst Fund are investors in Artoss.
Artoss CEO Paul Byerley said of Emley, “Charlie brings a lifetime of experience and a retinue of industry contacts to the Board.” Artoss COO and President Jim Cassidy said, “Charles Emley is the General Partner of Catalyst Fund, one of Artoss’ investors. Even before investing, Charlie was engaged with the management team and freely gave of his extensive knowledge and expertise.”
Dr. Gilbert Ortega is an orthopedic trauma surgeon in Scottsdale, Arizona, and member of the Artoss Clinical Advisory Board. He acts as co-director of Sonoran Orthopaedic Trauma Surgeons, the largest orthopedic trauma fellowship program in the United States. His extensive clinical background includes the treatment of polytraumatic injuries, complex fractures, and fracture non-unions. “Gil has provided valuable clinical feedback through our Clinical Advisory Board and will now add his first-hand experience with the U.S. healthcare system to our Board,” said Byerley.
Cassidy expressed Artoss’s excitement about its new board members, saying, “Charles Emley brings a diversity of experience in large and small companies as well as the U.S. government. As a consequence, his network is broad, and he has already called upon it on our behalf to address a number of finance-related questions that Artoss encountered.”
“Dr. Gilbert Ortega, as co-director of an orthopaedic fellowship program and a practicing trauma surgeon, provides insights into the emerging business and clinical challenges facing healthcare systems and surgeons. Together, they provide the management team with actionable intelligence on market conditions and opportunities.”
Following the shareholders meeting, a Board of Directors meeting was held, where Paul Byerley was elected Chief Executive Officer and James Cassidy, Ph.D. was elected Chief Operating Officer and President.
Artoss, Inc. was founded in 2015 and is based in St. Cloud, Minnesota. Artoss grew out of Artoss GmbH, a German company which was founded in 2003. Artoss specializes in applied nanotechnology, which it uses to create materials for bone repair. Its mission is “to bring the power of NanoBiology to bone repair through the clinically proven NanoBone® Bone Grafting technology.”
Artoss created the first synthetic bone graft approved for use in the U.S. in the 1990s and has patented NanoBone, a unique bone grafting technology. NanoBone incorporates nano-crystalline particles of hydroxyapatite that are similar in size, chemistry, and morphology to those that occur naturally in human bone.
